Cargando…

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma

Detalles Bibliográficos
Autores principales:	Parrondo, Ricardo D., Rahman, Zaid Abdel, Heckman, Michael G., Wieczorek, Mikolaj, Jiang, Liuyan, Alkhateeb, Hassan B., Litzow, Mark R., Greipp, Patricia, Sher, Taimur, Bergsagel, Leif, Fonseca, Rafael, Roy, Vivek, Dispenzieri, Angela, Kharfan-Dabaja, Mohamed A., Murthy, Hemant S., Ailawadhi, Sikander, Foran, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9160012/ https://www.ncbi.nlm.nih.gov/pubmed/35650175 http://dx.doi.org/10.1038/s41408-022-00680-y

Ejemplares similares

Comparative study of therapy‐related and de novo adult b‐cell acute lymphoblastic leukaemia
por: Abdel Rahman, Zaid H., et al.
Publicado: (2021)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature
por: Baksh, Mizba, et al.
Publicado: (2021)

Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH‐based algorithm distinguishes prognostic groups and outcomes
por: Abdel-Rahman, Zaid H., et al.
Publicado: (2021)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
por: Swaika, Abhisek, et al.
Publicado: (2017)

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
por: Jayakrishnan, Thejus, et al.
Publicado: (2021)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Primary diffuse large B‐cell lymphoma presenting as acute appendicitis: A report of 2 cases and a literature review
por: Fernandez Turizo, Maria Jose, et al.
Publicado: (2020)

Immunotherapy beyond cellular therapy in follicular lymphoma: A case of complete remission after failure of two CAR‐T
por: Kase, Adam M., et al.
Publicado: (2022)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

Clinical outcome of myelodysplastic syndrome progressing on hypomethylating agents with evolving frontline therapies: continued challenges and unmet needs
por: Ghorab, Ahmad, et al.
Publicado: (2022)

Cytokine Release Syndrome: Current Perspectives
por: Murthy, Hemant, et al.
Publicado: (2019)

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma
por: Alkhateeb, Hassan B., et al.
Publicado: (2022)

A Panel Evaluation of the Changes in the General Public’s Social-Media-Following of United States’ Public Health Departments during COVID-19 Pandemic
por: Khokhar, Areej, et al.
Publicado: (2021)

Primary peritoneal myeloid sarcoma in association with CBFB/MYH11 fusion
por: Kuhlman, Justin J., et al.
Publicado: (2021)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events
por: Abdelmagid, Maymona G., et al.
Publicado: (2023)

Hairy cell leukemia with CCND1/IGH fusion gene and BRAF V600E mutation
por: Rahman, Zaid Abdel, et al.
Publicado: (2020)

Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance
por: Ho, Matthew, et al.
Publicado: (2022)

Second symptomatic COVID-19 infections in patients with an underlying monoclonal gammopathy
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms
por: Gagnon, Marie-France, et al.
Publicado: (2022)

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
por: Kumar, Vivek, et al.
Publicado: (2019)

CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma
por: Mohty, Razan, et al.
Publicado: (2022)

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Recent advances in immunotherapy for B-cell non-Hodgkin lymphoma and multiple myeloma
por: Chavez, Julio C., et al.
Publicado: (2022)

Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
por: Zanwar, Saurabh, et al.
Publicado: (2022)

Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
por: Litzow, Mark R
Publicado: (2014)

Controversies and Recent Advances in Hematopoietic Cell Transplantation for Follicular Non-Hodgkin Lymphoma
por: Kanate, Abraham S., et al.
Publicado: (2012)

A Critical Appraisal of Extracorporeal Photopheresis as a Treatment Modality for Acute and Chronic Graft-Versus-Host Disease
por: Rafei, Hind, et al.
Publicado: (2017)

Therapeutic Approaches for Blastic Plasmacytoid Dendritic Cell Neoplasm: Allogeneic Hematopoietic Cell Transplantation and Novel Therapies
por: Kharfan-Dabaja, Mohamed A., et al.
Publicado: (2019)

Donor cell‐derived chronic myelomonocytic leukemia presenting after allogeneic hematopoietic cell transplantation for T‐cell acute lymphoblastic leukemia
por: Miller, Kevin C., et al.
Publicado: (2020)

Recent advances in the biology and treatment of B-cell acute lymphoblastic leukemia
por: Hefazi, Mehrdad, et al.
Publicado: (2018)

Management of toxicities associated with novel immunotherapy agents in acute lymphoblastic leukemia
por: Jain, Tania, et al.
Publicado: (2020)

Systemic ALK‐positive anaplastic large cell lymphoma with bilateral optic neurolymphomatosis resulting in permanent blindness
por: Seegobin, Karan, et al.
Publicado: (2020)

P580: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE
por: Basmaci, Rami, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oule9793srtmc8o5t52k5pivdj